Dasatinib, an oral TKI for both BCR-ABL and Src family, is also a second-line drug for patients with IM-resistant CML and able to inhibit the activation of exon 11Val560Asp or exon 17Asp816Val KIT mutants [11]. Here, KIT is linked to chronic myelogenous leukemia, BCR-ABL1 positive.